Welcome to our dedicated page for Horizon Therapeutics Pub L news (Ticker: HZNP), a resource for investors and traders seeking the latest updates and insights on Horizon Therapeutics Pub L stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Horizon Therapeutics Pub L's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Horizon Therapeutics Pub L's position in the market.
Summary not available.
Summary not available.
Horizon Therapeutics has shared promising data from the PROTECT trial, supporting KRYSTEXXA (pegloticase injection) for treating uncontrolled gout in kidney transplant patients. Presented at the ASN Kidney Week 2020, the trial indicates that patients receiving KRYSTEXXA showed significant reductions in serum uric acid levels. Among 15 enrolled patients, 5 completed treatment with sustained improvements, while 8 continued. The research highlights the drug's potential effectiveness without compromising kidney function, addressing a critical need among this vulnerable population.
Summary not available.
Summary not available.
Horizon Therapeutics plc (Nasdaq: HZNP) has announced new long-term data from its Phase 2 clinical trial of TEPEZZA (teprotumumab-trbw), showing sustained benefits in patients with Thyroid Eye Disease (TED) up to one year post-treatment. Key findings include that 97% of participants improved their clinical activity score and 70% achieved disease inactivation. TEPEZZA is the only FDA-approved treatment for TED, addressing a critical need for patients facing severe symptoms. These promising results support ongoing clinical evaluation and indicate the potential of TEPEZZA for long-term symptom relief.
Horizon Therapeutics plc (Nasdaq: HZNP) announced that new data on KRYSTEXXA (pegloticase injection) will be presented at the upcoming ACR Convergence conference from Nov. 5-9, 2020. This includes results from the RECIPE trial aimed at reducing immunogenicity of pegloticase in patients with uncontrolled gout. Presentations will focus on the impact of co-prescribing KRYSTEXXA with immunomodulators. Additionally, the company will host a discussion on Nov. 10 about these findings and their implications for treatment. Safety data indicate that the combination therapy's effectiveness remains unverified by health authorities.
Horizon Therapeutics plc (Nasdaq: HZNP) will announce its third-quarter 2020 financial results on November 2, 2020. A live webcast is scheduled for 8 a.m. Eastern Time to discuss the financial and operational performance. Interested parties can access the live stream and replay via the company's investor relations website.
Horizon focuses on developing medicines for rare and rheumatic diseases, aiming to provide clinically meaningful therapies through scientific expertise and compassion.
Summary not available.
HemoShear Therapeutics has achieved a significant milestone in its collaboration with Horizon Therapeutics (NASDAQ: HZNP) for developing new gout therapies. The partnership, initiated in January 2019, has led to valuable insights and the receipt of an undisclosed milestone payment. The collaboration could yield over $500 million in potential milestone payments and royalties for HemoShear. Additionally, HemoShear has received FDA approval to start a Phase 2 study for its oral drug targeting methylmalonic acidemia and propionic acidemia.